Previous close | 215.01 |
Open | 215.50 |
Bid | 214.59 x 800 |
Ask | 214.83 x 900 |
Day's range | 213.22 - 216.24 |
52-week range | 132.24 - 237.26 |
Volume | |
Avg. volume | 1,114,903 |
Market cap | 31.567B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 33.11 |
EPS (TTM) | 6.49 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | 1.92 (0.89%) |
Ex-dividend date | 08 May 2024 |
1y target est | 212.34 |
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.